"Compounded" and "brand" describe how a product is prepared, not a different active compound.
Branded pens arrive pre-mixed and dose in fixed clicks; compounded vials often arrive as powder to reconstitute.
That reconstitution step is the entire reason the concentration and units math becomes relevant.
US compounding of GLP-1s was allowed under the FDA drug-shortage exception during the 2022–2024 shortage.
Those shortages were declared resolved (tirzepatide Dec 2024, semaglutide Feb 2025), and the FDA has since moved to keep these drugs off the 503B bulks list — narrowing legal compounding.
"Compounded" and "brand" GLP-1 refer to how the product is prepared and supplied, not to a different active compound. The practical difference most people meet is that compounded product usually has to be reconstituted, while branded pens do not.
In plain terms: same class of drug, different packaging and preparation — and a very different regulatory status.
What compounding means
Compounding is the preparation of a medication outside the standard manufactured product — for example, as a lyophilized (freeze-dried) powder in a vial rather than a pre-filled pen. The intended active ingredient — semaglutide or tirzepatide — is the same GLP-1-pathway agonist either way.
That reconstitution step — choosing a water volume, computing a concentration, converting a dose to units — is the entire reason the calculator and reconstitution guides on this site exist for GLP-1s. The compounded, vial-based form is what makes the math relevant.
The regulatory context (this is the important part)
The status of compounded GLP-1s in the US is specific, and it has moved a lot. Here is the honest timeline:
During the shortage, compounding was permitted. US law allows compounders to prepare a drug that is on the FDA's official drug shortage list. Semaglutide and tirzepatide were added to that list during the 2022–2024 surge in demand, which is what opened the door to widespread compounded versions.
The shortages were then declared resolved — tirzepatide in December 2024 and semaglutide in February 2025 — and the FDA set phased deadlines for compounders to wind down1.
The FDA has since moved to keep these drugs off the 503B bulks list. In 2026 it proposed excluding semaglutide, tirzepatide, and liraglutide from that list, finding no clinical need to compound them from bulk substances absent a shortage2. That further narrows the legal basis for compounding.
In plain terms: compounded GLP-1s rode a shortage exception that has now closed, and the FDA is moving to keep it closed.
This page describes the practical preparation difference and the public regulatory facts only. It takes no position on sourcing, suitability, or where anyone should obtain anything — those are outside the scope of an educational reference, and are matters for a clinician and current law.
Whichever form, Zyra Labs tracks it the same way: log the dose, and it handles the schedule, inventory, and level curve.
Try it with the calculator
CONCENTRATION
2.5 mg/mL
YOUR DRAW (U-100)
40 units
DOSES IN VIAL
5
0102030405060708090100
Frequently asked
Why does compounded GLP-1 need reconstitution when the pens do not?
Branded pen products come pre-mixed and pre-measured. Compounded GLP-1 is often supplied as a lyophilized (freeze-dried) powder that the end user reconstitutes with bacteriostatic water, which is why the concentration and units math becomes relevant. The active compound is the same GLP-1 agonist.
Is the active drug different between compounded and brand?
The intended active ingredient is the same GLP-1-pathway agonist — semaglutide or tirzepatide. "Compounded" and "brand" refer to how the product is prepared and supplied, not to a different molecule. Manufacturing origin, purity, and oversight can differ, which is part of the regulatory picture below.
Was compounded GLP-1 ever legal in the US?
Yes, under a specific exception. When a drug is on the FDA shortage list, compounders may legally prepare it. Semaglutide and tirzepatide were on that list during the 2022–2024 shortage. The FDA later declared those shortages resolved, and has since moved to keep the drugs off the 503B bulks list — narrowing the legal basis for compounding.
References
U.S. Food & Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolution and enforcement wind-down).FDA.gov. 2025. FDA Drug Alerts & Statements
U.S. Food & Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on the 503B Bulks List.FDA.gov. 2026. FDA Press Announcement
Zyra Labs is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.